Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca
April 12, 2022 02:11 PM EDTUpdated April 13, 09:07 AM
R&D

As­traZeneca’s on­col­o­gy R&D chief Su­san Gal­braith high­lights their next-gen prospects at #AACR22

John Carroll

Editor & Founder

As­traZeneca’s turn­around sto­ry rests on the suc­cess of 3 big can­cer drugs: Lyn­parza, Tagris­so and more re­cent­ly En­her­tu. So what’s the fu­ture all about? …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times